Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke

Current Opinion in Cardiology

Volumn 22, Issue 4, 2007, Pages 359-367

  Walldius, Göran ^a,b   Jungner, Ingmar ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c CALAB Medical Laboratories   (Sweden)

Author keywords

Apolipoprotein A I; Apolipoprotein B apolipoprotein A I ratio; High density lipoprotein cholesterol; Myocardial infarction; Stroke

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; TORCETRAPIB;

ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SIDE EFFECT; STROKE;

APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; HUMANS; MYOCARDIAL INFARCTION; RISK FACTORS; STROKE;

EID: 34250208462     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3281bd8849     Document Type: Review

References (75)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002; 106:3144-3421.
2. Baigent C, Keech A, Kearney PM, et al., Cholesterol treatment trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
3. Szapary PO, Rader DJ. The triglyceride-high-density lipoprotein axis: an important target of therapy? Am Heart J 2004; 148:211-221.
4. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004; 255:188-205.
5. Barter PJ, Ballantyne CM, Carmena R, et al. ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirtyperson/ten-country panel. J Intern Med 2006; 259:247-258. In this recent paper 30 international researchers from 10 countries argue for the atherogenic lipoprotein particle paradigm: that the total number of atherogenic particles is a more important determinant of the risk of cardiovascular disease than any of the conventional lipid measures.
6. Chan DC, Watts GF. Apolipoproteins as markers and managers of coronary risk. Q J Med 2006; 99:277-287. In this recent Australian review the authors advocate that measurements of apolipoproteins should be routinely added to the routine lipid profile and that apolipoproteins also could replace the standard 'lipid profile' as a target for therapy in at-risk patients.
7. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy: a review of the evidence. J Intern Med 2006; 259:493-519. In this review the authors present evidence from recent Swedish and international studies indicating that apoB and apoA-I, especially the apoB/apoA-I ratio, are the best lipid-related summary index of cardiovascular risk. This ratio is also a strong predictor of outcome in lipid-lowering trials. The authors recommend that new guidelines should include apoB and apoA-I.
8. Sniderman AD, Marcovina SM. Apolipoprotein AI and B. Clin Lab Med 2006; 26:733-750. This recent Canadian-American overview is highly focused on apoB as a more powerful risk factor than the conventional cholesterol indices. More data are required to decide if the risk for CVD is best measured as HDL cholesterol or ApoA-I. At a technical level, however, apoA-I is clearly superior; its measurement is standardized, automated, and inexpensive.
9. Sacks FM. The apolipoprotein story. Atherosclerosis 2006; 7 (Suppl):23-27. This recent paper, by an American author, continues the debate and describes the clear advantages of using apoB as a predictor of coronary artery disease and how recent studies show its predictive superiority over LDL and non-HDL cholesterol.
10. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease: the Framingham Heart Study. Can J Cardiol 1988; 4 (Suppl A):5A-10A.
11. Rader DJ, Davidson MH, Caplan RJ, Pears JS. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin. Am J Cardiol 2003; 91 (Suppl):20C-24C.
12. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994; 121:641-647.
13. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358:2026-2033.
14. Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361:777-780.
15. Walldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med 2006; 259:259-266. This paper links the apoB/apoA-I ratio to the risk of fatal stroke in a similar fashion as for myocardial infarction and other ischemic events.
16. Walldius G, Jungner I, Aastveit AH, et al. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004; 42:1355-1363.
17. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006; 116:3090-3100. This overview presents advantages in our understanding of molecular regulation of HDL metabolism, macrophage cholesterol efflux, and HDL function that most likely will lead to a variety of novel therapeutics.
18. Packard CJ, Rader DJ, editors. Lipids and atherosclerosis. Advances in translational medical science. Abingdon, UK: Taylor & Francis Group; 2006. An excellent comprehensive overview of lipoprotein metabolism, which entails a wide variety of topics spanning several different disciplines and highlighting how advances in our basic understanding of lipoprotein metabolism can be translated to the development of new therapeutic agents.
19. Barter PJ, Rye K-A. The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med 2006; 259:447-454. This recent paper describes the key role of apoA-I as the main apolipoprotein of HDLs.
20. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001; 104:2376-2383.
21. Brites FD, Fernández KM, Verona J, et al. Chronic renal failure in diabetic patients increases lipid risk factors for atherosclerosis. Diab Res Clin Prac 2007; 75:35-41.
22. Castellani LW, Lusis AJ. ApoA-II versus ApoA-I: two for one is not always a good deal. Arterioscler Thromb Vasc Biol 2001; 21:1870-1872.
23. Luc G, Bard J-M, Ferrières J, et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease. The PRIME Study. Arterioscler Thromb Vasc Biol 2002; 22:1155-1161.
24. Corsetti JP, Zareba W, Moss AJ, et al. Elevated HDL is a risk factor for recurrent coronary events in a subgroup of nondiabetic postinfarction patients with hypercholesterolemia and inflammation. Atherosclerosis 2006; 187:191-197. This paper investigated interactions of inflammation with hyperlipidemia in generating CVD risk. They found a subgroup with elevated HDL which had an increased rather than decreased cardiovascular risk.
25. Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med 2006; 259:437-446. A recent paper describing how measurement of apolipoproteins has been internationally standardized and how, in contrast, the accuracy and comparability of the HDL and LDL cholesterol measurements are more problematic. Unlike apoA-I and apoB, there is no common reference material for these conventional lipid measurements. Also 'direct' HDL measurements have inherent method-dependent inaccuracies.
26. Sniderman AD, Blank D, Zakarian R, et al. Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. Clin Biochem 2003; 36:499-504.
27. Sniderman AD, Jungner I, Holme I, et al. Errors that result from using the TC/HDL-C ratio rather than apoB/apoA-I ratio to define the lipoprotein related risk of vascular disease. J Intern Med 2006; 259:455-461.
28. Charlton-Menys V, Durrington P. Apolipoproteins A-I and B as therapeutic targets. J Intern Med 2006; 259:462-472. This paper emphasizes that raising low levels of HDL, probably best measured as apoA-I, may prove to be an important aim of treatment. The apoB/apoA-I ratio could easily replace the total cholesterol/HDL cholesterol ratio used in CVD risk prediction. Automated apoA-I immunoassay is a much better alternative than the HDL cholesterol measurements used today in virtually all clinical laboratories. ApoB would be a superior target to optimize statin therapy.
29. Stein EA. Analytical issues and their clinical impact: lipoproteins. NACB Symposium; Baltimore, USA; 21 October 2006. Version 091906. http://www.aacc.org/AACC/members/nacb/LMPG/OnLineGuide/DraftGuidelines/ Emerg_Risk_Factors/default.htm. [Accessed 13 April 2007] Based on CAP survey data the author demonstrates that apoB measurements are well 'standardized' and reproducible between labs, that apoB measurements are widely available and more 'reliable' in 2006 than either 'direct' LDL cholesterol or 'homogeneous' HDL cholesterol, that apoA-I is now readily analyzed by most large labs and that apoA-I performance is still better than for 'homogeneous' HDL cholesterol which is now widely used.
30. College of American Pathologists (CAP) Comprehensive Chemistry Participant Survey. Reports 2005, 2006.
31. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III: Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 1993; 39:773-781.
32. Ritchie RF, Palomaki GE, Neveux LM, et al. Reference distributions for apolipoproteins AI and B and the apolipoprotein B/AI ratios: a practical and clinically relevant approach in a large cohort. J Clin Lab Anal 2006; 20:209-217. This major study presents data which provide a firm basis for comparison with preexisting reference intervals and for establishing a clinically useful and current reference interval for the apoB and apoA-I values.
33. Ritchie RF, Palomaki GE, Neveux LM, et al. Reference distributions for apolipoproteins AI and B and B/AI ratios: comparison of a large cohort to the world's literature. J Clin Lab Anal 2006; 20:218-226. Great technological strides have been made in the last few years. The remaining barrier to more relevant and cost-effective use of serum data for diagnosis and prognosis has been the availability of widely recognized reliable reference intervals from birth to old age for both males and females. A total of 82 publications reporting reference intervals have been identified.
34. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 1:16-19.
35. Rosenson RS. Low HDL-C: a secondary target of dyslipidemia therapy. Am J Med 2005; 118:1067-1077.
36. Rader DJ. High-density lipoproteins as an emerging therapeutic target for atherosclerosis. JAMA 2003; 290:2322-2324.
37. Gotto AM, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease. J Am Coll Cardiol 2004; 43:717-724.
38. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004; 27 (Suppl 1):S68-S71.
39. Tremblay AJ, Sniderman AD, Gagné C, et al. Differential impact of plasma triglycerides on HDL-cholesterol and HDL-apo A-I in a large cohort. Clin Biochem 2007; 40:25-29.
40. Zambon A, Brown BG, Debb SS, Brunzell JD. Genetics of apolipoprotein B and apolipoprotein A-I and premature coronary artery disease. J Intern Med 2006; 259:473-480. This recent genetic paper emphasizes the clinical relevance of apolipoproteins, and especially of the apoB/apoA-I ratio, as predictor of CAD risk, and how this is fully confirmed by the analysis of the familiar forms of dyslipidemia.
41. Sirtori CR, Calabresi L, Franceschini C, et al. Cardiovascular status of carriers of the apolipoprotein A-I (Milano) mutant: the Limone sul Garda Study. Circulation 2001; 103:1949-1954.
42. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290:2292-2300.
43. Calabresi L, Sirtori CR, Paoletti R, Franceschini G. Recombinant apolipoprotein A-I Milano for the treatment of cardiovascular disease. Curr Atheroscler Rep 2006; 8:163-167. The authors reported that in a phase II trial in patients with acute coronary syndromes short-term treatment with apoA-I (Milano) caused a remarkable reduction in the atheroma burden.
44. Avogaro P, Bon G, Cazzolato G, Quinci G. Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet 1979; 1:901-903.
45. Fager G, Wiklund O, Olofsson SO, et al. Serum apolipoprotein levels in relation to acute myocardial infarction and its risk factors. Atherosclerosis 1980; 36:67-74.
46. Durrington PN, Livingstone S, Carlton-Menys V, et al. Apolipoproteins as predictors of cardiovascular risk in the Collaborative AtoRvastatin Diabetes Study (CARDS) [abstract]. In: XIV International Symposiumon Atherosclerosis; Rome, Italy; 20 June 2006. p. 37.
47. Qureshi AI, Giles WH, Croft JB, Guterman LR, et al. Apolipoprotein A-I and B and the likelihood of nonfatal stroke and myocardial infarction: data from the Third National Health and Nutrition Examination Survey. Med Sci Monit 2002; 8:CR311-CR316.
48. Möller CS, Zethelius B, Sundström J, Lind L. Impact of follow-up time and re-measurement of the electrocardiogram and conventional cardiovascular risk factors on their predictive value for myocardial infarction. J Intern Med 2006; 260:22-30.
49. Sharp DS, Burchfiel CM, Rodriguez BL, et al. Apolipoprotein A-I predicts coronary heart disease only at low concentrations of high-density lipoprotein cholesterol: an epidemiological study of Japanese-Americans. Int J Clin Lab Res 2000; 30:39-48.
50. Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006; 259:481-492. This recent paper is a literature-based metaanalysis of prospective studies to assess associations of circulating levels of apoA-I, apoB, apoB/apoA-I and coronary heart disease.
51. Florvall G, Basu S, Larsson A. Apolipoprotein A1 is a stronger prognostic marker than are HDL and LDL cholesterol for cardiovascular disease and mortality in elderly men. J Gerontol Biol Sci Med Sci 2006; 61A:1262-1266.
52. Yusuf S, Hawken S, Öunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952.
53. Lind L, Vessby B, Sundström J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol 2006; 26:406-410. A recent paper relating apoB/apoA-I to the metabolic syndrome as well as to a direct measurement of insulin resistance.
54. Sierra-Johnson J, Somers VK, Kuniyoshi FH, et al. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am J Cardiol 2006; 98:1369-1373. These authors conclude that the apoB/apoA-I is strongly associated with the presence of individual components of the metabolic syndrome, with the metabolic syndrome itself, and with insulin resistance.
55. Wallenfeldt K, Bokemark L, Wikstrand J, et al. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 2004; 35:2248-2252.
56. Di Napoli P, Taccardi AA, Oliver M, De Caterina R. Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J 2002; 23:1908-1921.
57. Curb JD, Abbott RD, Rodriquez BL, et al. High density lipoprotein cholesterol and the risk of stroke on elderly men: the Honolulu Heart Program. Am J Epidemiol 2004; 160:150-157.
58. Tirschwell DL, Smith NL, Heckbert SR, et al. Association of cholesterol with stroke risk varies in stroke subtypes and patient groups. Neurology 2004; 63:1868-1875.
59. Weverling- Rijnsburger AWF, Jonkers IJAM, van Exel E, et al. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med 2003; 163:1549-1554.
60. Soyama Y, Miura K, Morikawa Y, et al. High-density lipoprotein cholesterol and risk of stroke in Japanese men and women: the Oyabe Study. Stroke 2003; 34:863-868.
61. Witt BJ, Brown RD, Jacobsen SJ, et al. A community-based study of stroke incidence after myocardial infarction. Ann Intern Med 2005; 143:785-792.
62. Gardner CD, Tribble DI, Young DR, et al. Associations of HDL, HDL2, and HDL3 cholesterol and apolipoproteins A-I and B with lifestyle factors in healthy women and men: the Stanford Five City Project. Prev Med 2000; 31:346.
63. Leiter LA, Rosenson RS, Stein E, et al., on behalf of the POLARIS study investigators. Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007; 15 January [Epub ahead of print].
64. Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Ann Intern Med 2000; 160:1177-1184.
65. Durrington PN, Tuomilehto J, Hamann A, et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 2004; 64:137-151.
66. Jukema JW, Liem AH, Dunselman PH, et al. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in Different Dosages and Reverse Cholesterol Transport) study. Curr Med Res Opin 2005; 21:1865-1874.
67. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101:477-484.
68. Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002; 105:1162-1169.
69. Olsson A, Holme I, Pedersen TR for the IDEAL Steering Committee and Investigators. Apolipoprotein B/A-I ratio is a better discriminator of risk of coronary heart disease than is LDL/HDL cholesterol ratio in the IDEAL study [abstract]. In: XIV International Symposium on Atherosclerosis; Rome, Italy; 20 June 2006. p. 161.
70. Kastelein JJ, Holme I, Barter P, et al. Superiority of ApoB/ApoA-I ratio for predicting cardiovascular risk in pooled analyses of the Incremental Decrease in Endpoints through Aggressive Lipid-Lowering (IDEAL) and Treating to New Targets (TNT) Trials [abstract]. American Heart Association; 15 November 2006.
71. Nicholls SJ, Tuzen EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297:499-508. This excellent paper describes the relationship between statin-induced changes in HDL cholesterol and atheroma progression determined by IVUS. Regression of coronary atherosclerosis was observed when LDL cholesterol was substantially reduced and HDL cholesterol was increased more than 7.5%. The apoB/apoA-I ratio was the strongest lipid predictor of changes in atheroma burden. This paper will hopefully generate additional interest in the question, how do we best monitor lipid-lowering therapy?
72. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it a molecule or the mechanism? Arterioscler Thromb Vascular Biol 2007; 27:257-260.
73. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. New Engl J Med 2007; 356:1304-1316.
74. Kastelein JP, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356(16):1620-1630.
75. Tall AR. CETP inhibitors to increase HDL cholesterol levels. New Engl J Med 2007; 356:13.